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We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the
Polish population. The study group consisted of 66 Polish families with cancer who have at least three related
females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected
females, at age !50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers
only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes
of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened
for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants.Mutations
were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1
gene. BRCA1 abnormalities were identiﬁed in all four families with ovarian cancer only, in 67% of 27 families
with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a
BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identiﬁed; ﬁve of these
occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with
detected mutations. Three BRCA1 abnormalities—5382insC, C61G, and 4153delA—accounted for 51%, 20%,
and 11% of the identiﬁed mutations, respectively.
Mutations in BRCA1 (MIM 113705) and BRCA2 (MIM
600185) confer a high lifetime risk for both breast and
ovarian cancer (Futreal et al. 1994; Miki et al. 1994;
Wooster et al. 1994, 1995). Many different BRCA1 and
BRCA2 mutations have been described in families with
early-onset breast and ovarian cancer (Couch et al. 1996;
Couch and Weber 1996). The presence of recurrent mu-
tations in BRCA1 suggests the presence of founder ef-
fects; this was ﬁrst conﬁrmed in the Ashkenazi Jewish
population (Tonin et al. 1995, 1996). Founder muta-
tions in other populations have also been described.
To identify possible founder mutations in individuals in
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Poland, we evaluated a panel of 66 Polish families
with familial aggregation of breast or ovarian cancers.
Knowledge of the nature and frequency of population-
speciﬁc mutations in BRCA1 and BRCA2 is a critical
step in the development of simple and inexpensive di-
agnostic approaches to DNA analysis in particular eth-
nic groups.
The study group consisted of 66 Polish families with
breast-ovarian cancer who were drawn from the On-
cology Centers in Szczecin (58 families), Wrocław (5
families) and Ło´dz´ (3 families), Poland. In each family,
at least three related female relatives were affected by
breast or ovarian cancer, and at least one cancer was
diagnosed at a patient age !50 years. A total of 27 fam-
ilies had both breast and ovarian cancers, whereas 4
families had ovarian cancers only and 35 families had
breast cancer only.
Blood samples for genetic analyses were taken from
at least one affected woman from each family; generally,
the samples were taken from the youngest of these
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Table 1
Frequency of BRCA1 and BRCA2 Mutations, Depending on the Site
of Origin of Cancers in a Family
CANCER
FREQUENCY OF MUTATION
BRCA1 BRCA2 Total
Breast and ovarian 18/27 (66.7%) 1/27 (3.7%) 19/27 (70.4%)
Ovarian only 4/4 (100%) 0/4 (0%) 4/4 (100%)
Breast only 12/35 (34.3%) 0/35 (0%) 12/35 (34.3%)
Total 34/66 (51.5%) 1/66 (1.5%) 35/66 (53%)
women. Genomic DNA was prepared from peripheral
blood leukocytes, by use of the nonenzymatic, rapid
method described by Lahiri and Nurnberger (1991). The
entire coding region of BRCA1 and BRCA2 was
screened for the presence of germline mutations in
BRCA1 and BRCA2, by use of SSCP followed by direct
sequencing of variants. The primers used for PCR am-
pliﬁcation of the BRCA1 gene have been described in
the Breast Cancer Information Core (BIC) database, and
those used for BRCA2 have been described by Friedman
et al. (1997). Samples were sequenced with the use of
ﬂuorescently labeled dideoxy-chain terminators (Sanger
et al. 1997) from the ABI Prism Kit (PE Biosystems), in
a model 373 automated DNA sequencer (PE Biosys-
tems). Members of families with detected mutations
were interviewed to identify the geographic regionwhere
their ancestors lived before World War II.
Mutations were found in 35 (53%) of the 66 families
studied. All but one of the mutations were detected
within the BRCA1 gene. The mutation-detection rate
was dependent on the number of ovarian cancers:
BRCA1 abnormalities were identiﬁed in 100% of four
families with ovarian cancers only, in 67% of 27 families
with breast and ovarian cancers, and in 34% of 35 fam-
ilies with breast cancers only (table 1). The single family
with a BRCA2 mutation presented with the breast-ovar-
ian cancer syndrome.
Seven distinct mutations were identiﬁed, and ﬁve of
these occurred in at least two different families (table
2). Recurrent alterations were found in 33 (94%) of the
35 families with detected mutations. Three BRCA1 mu-
tations—5382insC, C61G, and 4153delA—accounted
for 51%, 20%, and 11% of all identiﬁed mutations,
respectively.
For individuals from families with mutations and for
individuals from families without detected mutations,
the average age at diagnosis of breast cancers was 47.8
and 48.2 years, respectively. For families with BRCA1
mutations, the average age at diagnosis of ovarian can-
cers was 44.4 years.
It was possible to establish the family area of origin
before World War II, for 25 probands with BRCA1 mu-
tations. This was done with reference to the branch of
the family that was most likely to be transmitting the
mutation. No particular geographic aggregation of mu-
tations was observed (ﬁg. 1).
The results of the present study suggest that Poland
can now be included in the select group of countries in
which a small number of founder mutations accounts
for the majority of changes in families with BRCA1 and
BRCA2 and a genetic predisposition to breast and ovar-
ian cancers. Three BRCA1 abnormalities—5382insC,
C61G, and 4153delA—were found in 82% of families
with a strong aggregation of breast or ovarian cancers,
and they were found in 94% of families with detected
mutations.
Other ethnic groups with high frequencies of founder
mutations include Ashkenazi Jews, Icelanders, French
Canadians, the Dutch, Norwegians, Swedes, and, pos-
sibly, other populations of central and eastern Europe
(Streuwing et al. 1995; Szabo and King 1997; Dorum
et al. 1999; table 3).
The most frequent mutation in the present series was
the BRCA1 5382insC, which occured in approximately
one-half of the families with mutations. The majority of
families with this common mutation originate from east-
ern or central Europe. This mutation is also common in
Ashkenazi Jews, and it constitutes ∼25% of the muta-
tions found in Jewish women with a high genetic risk
of breast and ovarian cancers (Struewing et al. 1997).
The ﬁndings from small case series suggest that the
5382insC mutation also occurs frequently in families
from Hungary and Latvia who have breast-ovarian can-
cer (Gayther et al. 1997; Ramus et al. 1997; Csokay et
al. 1999).
The individuals analyzed in this study were collected
predominantly from northwest Poland. However, be-
cause most of the migration (from all regions of Poland)
to this northwest region occured after World War II, we
believe that these mutations are representative of mu-
tations in individuals in the country at large (ﬁg. 1).
Furthermore, the results of independent studies have ver-
iﬁed that BRCA1 5382insC is the dominant founder
mutation in Silesia, which is a southern region of Poland
(E.G., personal communication).
The second most commonly observed mutation in the
present study was the BRCA1 C61G missense mutation
in exon 5, which accounted for 20% of families with
mutations. This mutation has previously been reported
in various ethnic groups; however, to our knowledge, its
incidence in Poland is higher than that in any population
described to date, suggesting that this BRCA1 abnor-
mality is characteristic of the Polish population.
The third recurrent mutation found in Polish patients,
BRCA1 4153delA, was detected in 6% of Polish fami-
lies. This mutation has previously been described and
has been found in multiple families fromRussia (Gayther
et al. 1997). Thus, the 4153delA mutation appears to
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Table 2
Germline Mutations Detected in BRCA1 and BRCA2 Genes in Families from Poland Who Have
Breast and/or Ovarian Cancer
GENE AND
FAMILY
NUMBER
MUTATION SITE AND NO. OF CANCERS
Exon Codon Alteration Breast Ovaries Other
BRCA1:
4506 20 1756 5382insC 3 ) )
3311 20 1756 5382insC 3 ) )
4412 20 1756 5382insC 3 ) )
1633 20 1756 5382insC 3 ) Colon
4508 20 1756 5382insC 2 1 )
3319 20 1756 5382insC 2 1 )
3088 20 1756 5382insC 2 2 Lymphoma
3572 20 1756 5382insC 3 ) )
4545 20 1756 5382insC 3 ) Colon, stomach
1738 20 1756 5382insC 4 3 Colon
1582 20 1756 5382insC 3 ) Prostate
4478 20 1756 5382insC 3 ) )
1387 20 1756 5382insC 4 1 Colon
2863 20 1756 5382insC 4 2 )
4968 20 1756 5382insC ) 4 Stomach, cancer site unknown
5715 20 1756 5382insC ) 3 )
5726 20 1756 5382insC 1 2 )
4030 20 1756 5382insC 3 ) Lung, leukemia
1581 5 61 C61G 2 2 Cancer site unknown
1888 5 61 C61G 4 ) )
4859 5 61 C61G 3 ) )
3804 5 61 C61G 7 ) )
4858 5 61 C61G 4 ) )
5850 5 61 C61G 2 1 )
4854 5 61 C61G 3 ) Skin
2984 11 1345 4153delA 2 1 )
4278 11 1345 4153delA ) 4 )
3080 11 1345 4153delA 2 2 Colon
5939 11 1345 4153delA ) 4 Leukemia
1601 2 23 185delAG 3 ) )
703 2 23 185delAG 3 ) Lung
3910 11 1234 3819del5 3 ) )
5763 11 1234 3819del5 2 2 Colon, lung
5746 5 64 C64R 4 1 Lung, colon, leukemia
BRCA2:
3874 27 3401 T3401M 2 1 Colon
be another BRCA1 mutation characteristic of individ-
uals in eastern Europe.
The 185delAG mutation is the second BRCA1 ab-
normality that is common to both the Polish and the
Ashkenazi populations. In combination, the 5382insC
and 185delAG BRCA1 mutations account for ∼60% of
the total BRCA1 and BRCA2 mutations in Poland and
in the Ashkenazi population. This similarity may reﬂect
the common history of these two populations. In some
instances, Polish families with these mutations may be
descendants of individuals who converted from Judaism
in recent generations.
The ﬁnal recurrent mutation found in this study was
the 3819del5 BRCA1 mutation. This mutation has not
previously been reported, and it may be characteristic
of the Polish population.
Other Polish families with BRCA1 or BRCA2 muta-
tions have been reported (see the BIC database; Sobczak
et al. 1997; Jakubowska et al. 1999). Mutations that
have been reported in other studies of Polish families
but that are not present in the population studied here
include BRCA1 W1782X (Sobczak et al. 1997) and
BRCA2 T3401M, 6886del5, 7883del4, and 9630delC
(see the BIC database; Jakubowska et al. 1999). The
9630delC mutation was present in three families from
Silesia (E.G., personal communication).
It is possible that we have not yet identiﬁed all founder
mutations that occur in Poland. SSCP does not detect
all mutations, and the technique used here is not sensitive
to the detection of large deletions or duplications. How-
ever, the proportion of families with detected mutations
was high; mutations were identiﬁed in 70% of families
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Figure 1 Map with localization of geographic areas where an-
cestors of BRCA1-mutation carriers were living before World War II.
Table 3
Populations with a High Proportion of BRCA1 and BRCA2 Founder
Mutations
POPULATION
MUTATION
REFERENCEBRCA1 BRCA2
Ashkenazi Jews 185delAG Simard et al. (1994)
5382insC
6174delT Neuhausen et al. (1996)
British 4184del4 Gayther et al. (1995)
6503delTT Mazoyer et al. (1996)
Icelanders 999del5 Thorlacius et al. (1996)
Dutch 2804delAA Peelan et al. (1997)
2312del5 Petrij-Bosch et al. (1997)
1411insT
C2457T
Norwegians 1135insA Andersen et al. (1996)
1675delA Dorum et al. (1997)
Swedes 2594delC Johannsson et al. (1996)
C1806T Hakansson et al. (1997)
3172ins5
1201del11
3829delT
4486delG Hakansson et al. (1997)
A3508T
4075delGT
Russians 5382insC Gayther et al. (1997)
4153delA
with breast and ovarian cancers and in 34% of families
with breast cancers only; therefore, it is unlikely that we
have missed many mutations. It is possible that there
are local founder mutations that are speciﬁc to subre-
gions of Poland and that are not represented here. Fur-
thermore, we have sequenced only a single individual
per family, and it is possible that we have inadvertently
chosen to sequence a sporadic case in a family in which
a mutation is present in other affected individuals.
Of note is the preponderance of BRCA1 mutations
over BRCA2 mutations in the present series. To our
knowledge, this is the most extreme example of an excess
of BRCA1 mutations over BRCA2 mutations in a par-
ticular population. The results of epidemiological studies
in the United Kingdom, Canada, the United States, and
Israel suggest that BRCA2 mutations account for 40%
of all mutations identiﬁed in families with breast-ovarian
cancer and for the majority of mutations in families with
site-speciﬁc breast cancer (Easton et al. 1995; Couch et
al. 1996; Peto et al. 1999). Examples of populations in
which there are predominantly BRCA2 mutations in-
clude Iceland (Thorlacius et al. 1997), Italy (Santarosa
et al. 1998), and the Philippines (S.A.N., unpublished
data). In the present study, BRCA2 mutations were
found in only 1.5% of all families with an aggregation
of breast or ovarian cancer. The reason for the prepon-
derance of BRCA1 mutations in this population is not
clear. The most likely explanation is that the founder
effects were restricted to this gene. We do not believe
that the families were selected for the study in a way
that preferentially led to the inclusion of BRCA1-posi-
tive families. Although 45% of the families in the present
series included one or more cases of ovarian cancer, the
number of BRCA1 mutations far exceeded the number
of BRCA2 mutations in families with site-speciﬁc breast-
cancer syndrome. In fact, all 12 mutations in families
with site-speciﬁc breast cancer were found in BRCA1
(table 1).
The results of the present study will be of signiﬁcance
both for diagnostic testing and for epidemiological stud-
ies. BRCA1 and BRCA2 are both large genes, and com-
plete analysis of the coding regions is expensive and
time-consuming. The identiﬁcation of ﬁve founder mu-
tations allows for the rapid diagnosis of BRCA1-mu-
tation carriers in Polish individuals with relatively high
sensitivity. Furthermore, in countries with a large Polish
population, such as the United States, DNA testing for
founder mutations prior to complete gene analyses may
be cost-effective. The simplicity of detection of the
BRCA1 mutation in Poland creates a unique opportunity
for rapid identiﬁcation of hundreds and, possibly,
thousands of Polish women who carry constitutional
mutations. This group will be exceedingly valuable for
use in the study of chemoprevention and treatment in
high-risk women.
Acknowledgments
We thank Dr. R. Scott and Dr. H. Sobol, for critical reading
of the manuscript. This work was supported by Polish Na-
Reports 1967
tional Scientiﬁc Committee grants KBN No4P05A 06416 and
KBN No4P05A 09516.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
BIC, http://www.nhgri.nih.gov/Intramural_research/
Lab_transfer/Bic/ (for BRCA1 and BRCA2 mutations)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for BRCA1 [MIM 113705] and
BRCA2 [MIM 600185])
References
Andersen T, Børresen A-L, Møller P (1996) A commonBRCA1
mutation in Norwegian breast and ovarian cancer families?
Am J Hum Genet 59:486–487
Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K,
Campeau L, Peng Y, et al (1996) BRCA2 germlinemutations
in male breast cancer cases and breast cancer families. Nat
Genet 13:123–125
Couch FJ, Weber BL (1996) Mutations and polymorphisms in
the familial early-onset breast cancer (BRCA1) gene. Breast
Cancer Information Core. Hum Mutat 8:8–18
Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E
(1999) Strong founder effects in BRCA1 mutation carrier
breast cancer patients from Latvia: mutation in brief no.
258. Online. Hum Mutat 14:92
Dorum A, Hovig E, Trope C, Inganas M, Moller P (1999)
Three per cent of Norwegian ovarian cancers are caused by
BRCA1 1675delA or 1135insA. Eur J Cancer 35:779–781
Dorum A, Moller P, Kamsteeg EJ, Scheffer H, BurtonM,Heim-
dal KR, Maehle LO, et al (1997) A BRCA1 founder mu-
tation, identiﬁed with haplotype analysis, allowing geno-
type/phenotype determination and predictive testing. Eur J
Cancer 33:2390–2392
Easton DF, Ford D, Bishop DT, the Breast Cancer Linkage
Consortium (1995) Breast and ovarian cancer incidence in
BRCA1-mutation carriers. Am J Hum Genet 56:265–271
Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B,
Casey G, Ponder PA, et al (1997) Mutation analysis of
BRCA1 and BRCA2 in a male breast cancer population. Am
J Hum Genet 60:313–319
Futreal PA, Liu QY, Shattuck-Eidens D, Cochran C, Harshman
K, Tavtigian S, Bennett LM, et al (1994) BRCA1 mutations
in primary breast and ovarian carcinomas. Science 266:
120–122
Gayther SA, Harrington P, Russell P, Kharkevich G, Garkav-
tseva RF, Ponder BAJ (1997) Frequently occurring germ-line
mutations of the BRCA1 gene in ovarian cancer families
from Russia. Am J Hum Genet 60:1239–1242
Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington
PA, Chiano M, Seal S, et al (1995) Germline mutations of
the BRCA1 gene in breast and ovarian cancer families pro-
vide evidence for a genotype-phenotype correlation. Nat Ge-
net 11:428–433
Ha˚kansson S, Johannsson O, Johansson U, Sellberg G, Loman
N, Gerdes A-M, Holmberg E, et al (1997) Moderate fre-
quency of BRCA1 and BRCA2 germ-line mutations in Scan-
dinavian familial breast cancer. Am J Hum Genet 60:
1068–1078
Jakubowska A, Gronwald J, Huzarski T, Byrski T, Menkiszak
J, Lubinski J (1999) Human gene mutations. Hum Genet
105:293
Johannsson O, Ostermeyer EA, Ha˚kansson S, Friedman LS,
Johansson U, Sellberg G, Brøndum-Nielsen K, et al (1996)
Founding BRCA1 mutations in hereditary breast and ovar-
ian cancer in southern Sweden. Am J Hum Genet 58:441–
450
Lahiri DK, Nurnberger JI Jr (1991) A rapid non-enzymatic
method for the preparation of HMW DNA from blood for
RFLP studies. Nucleic Acids Res 19:5444
Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N,
Healey CS, Gayther SA, et al (1996) A polymorphic stop
codon in BRCA2. Nat Genet 14:253–254
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman
K, Tavtigian S, Liu QY, et al (1994) A strong candidate for
the breast and ovarian cancer susceptibility gene BRCA1.
Science 266:66–71
Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swen-
sen J, Hampel H, et al (1996) Recurrent BRCA2 6174delT
mutations in Ashkenazi Jewish women affected by breast
cancer. Nat Genet 13:126–128
Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C,
van den Ouweland AMW, Hogervorst F, et al (1997) A high
proportion of novel mutations in BRCA1 with strong foun-
der effects among Dutch and Belgian hereditary breast and
ovarian cancer families. Am J Hum Genet 60:1041–1049
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N,
Easton DF, et al (1999) Prevalence of BRCA1 and BRCA2
gene mutations in patients with early-onset breast cancer. J
Natl Cancer Inst 91:943–949
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk RV, Olmer R,
Drusedau M, Hogervorst FB, et al (1997) BRCA1 genomic
deletions are major founder mutations in Dutch breast can-
cer patients. Nat Genet 17:341–345
Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M,
Gayther SA, Csokay B, Ponder BAJ, et al (1997) Analysis
of BRCA1 and BRCA2 mutations in Hungarian families
with breast or breast-ovarian cancer. Am J Hum Genet
60:1242–1246
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with
chain-terminating inhibitors. Proc Natl Acad Sci USA 74:
5463–5467
Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD,
Pizzichetta MA, Tibiletti MG, et al (1998) Low incidence
of BRCA1 mutations among Italian families with breast and
ovarian cancer. Int J Cancer 78:581–586
Simard J, Tonin P, Durocher F, et al (1994) Common origins
of BRCA1 mutations in Canadian breast and ovarian cancer
families. Nat Genet 8:392–398
Sobczak K, Kozlowski P, Napierala M, Czarny J, Wozniak M,
Kapuscinska M, Losko M, et al (1997) Novel BRCA1 mu-
tations and more frequent intron-20 alteration found among
236 women from Western Poland. Oncogene 15:1773–1779
Streuwing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM,
Collins FS, Brody LC (1995) The carrier frequency of the
1968 Am. J. Hum. Genet. 66:1963–1968, 2000
BRCA1 185delAG mutatiom is approximately 1 percent in
Ashkenazi Jewish individuals. Nat Genet 11:198–200
Streuwing JP, Hartge P, Wacholder S, Baker SM, Berlin M,
McAdams M, Timmerman MM, et al (1997) The risk of
cancer associated with speciﬁc mutations of BRCA1 and
BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–
1408
Szabo CI, King M-C (1997) Population genetics of BRCA1
and BRCA2. Am J Hum Genet 60:1013–1020
Thorlacius S, Olafsdottir S, Tryggvadottir L, Neuhausen S,
Jonasson JG, Tavtigian SV, Tulinius H, et al (1996) A single
BRCA2 mutation in male and female breast cancer families
from Iceland with varied cancer phenotypes. Nat Genet 13:
117–121
Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jon-
asson JG, Tryggvadottir L, Tulinius H, et al (1997) Study
of a single BRCA2 mutation with high carrier frequency in
a small population. Am J Hum Genet 60:1079–1084
Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J,
Morgan K, et al (1995) BRCA1 mutations in Ashkenazi
Jewish women. Am J Hum Genet 57:189
Tonin P, Weber B, Ofﬁt K, Couch F, Rebbeck TR, Neuhausen
S, Godwin AK, et al (1996) Frequency of recurrent BRCA1
and BRCA2 mutations in Ashkenazi Jewish breast cancer
families. Nat Med 2:1179–1183
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion
J, Collins N, et al (1995) Identiﬁcation of the breast cancer
gene BRCA2. Nature 378:789–792
Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins
N, Nguyen K, et al (1994) Location of a breast cancer sus-
ceptibility gene, BRCA2, to chromosome 13q12-13. Science
265:2088–2090
